Familial lung cancer: A brief history from the earliestwork to the most recent studies

Genes

Volumn 8, Issue 1, 2017, Pages

  Musolf, Anthony M ^a   Simpson, Claire L ^a,b   De Andrade, Mariza ^c   Mandal, Diptasri ^d   Gaba, Colette ^e   Yang, Ping ^c   Li, Yafang ^f   You, Ming ^g   Kupert, Elena Y ^g   Anderson, Marshall W ^g   Schwartz, Ann G ^h   Pinney, Susan M ⁱ   Amos, Christopher I ^f   Bailey Wilson, Joan E ^a  

^a NATIONAL HUMAN GENOME RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^c MAYO CLINIC   (United States)

^d LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e MEDICAL COLLEGE OF OHIO   (United States)

^f DARTMOUTH MEDICAL SCHOOL   (United States)

^g MEDICAL COLLEGE OF WISCONSIN   (United States)

^h WAYNE STATE UNIVERSITY   (United States)

ⁱ UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

Family studies; Linkage; Lung cancer; Major gene; Susceptibility

Indexed keywords

TOBACCO SMOKE;

ALLELE; CANCER RISK; ENVIRONMENTAL EXPOSURE; GENETIC ASSOCIATION; GENETIC LINKAGE; GENETIC VARIABILITY; GENOME-WIDE ASSOCIATION STUDY; GERMLINE MUTATION; HEREDITARY TUMOR; HUMAN; LINKAGE ANALYSIS; LUNG CANCER; REVIEW; SEGREGATION ANALYSIS;

EID: 85010289421     PISSN: None     EISSN: 20734425     Source Type: Journal    
DOI: 10.3390/genes8010036     Document Type: Review

References (95)

1. Beckett, W.S. Epidemiology and etiology of lung cancer. Clin. Chest Med. 1993, 14, 1-15.
2. Cancer Facts & Figures 2016. Available online: http://www.cancer.org/acs/groups/content/@research/documents/document/acspc-047079.pdf (accessed on 12 September 2016).
3. Howlader, N.N.A.; Krapcho, M.; Miller, D.; Bishop, K.; Altekruse, S.F.; Kosary, C.L.; Yu, M.; Ruhl, J.; Tatalovich, Z.; Mariotto, A. et al. Seer Cancer Statistics Review; National Cancer Institute: Bethesda, MD, USA, 1975-2013.
4. National Lung Screening Trial Research Team; Aberle, D.R.; Adams, A.M.; Berg, C.D.; Black, W.C.; Clapp, J.D.; Fagerstrom, R.M.; Gareen, I.F.; Gatsonis, C.; Marcus, P.M. et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. N. Engl. J. Med. 2011, 365, 395-409.
5. Wender, R.; Fontham, E.T.; Barrera, E., Jr.; Colditz, G.A.; Church, T.R.; Ettinger, D.S.; Etzioni, R.; Flowers, C.R.; Gazelle, G.S.; Kelsey, D.K. et al. American cancer society lung cancer screening guidelines. CA: Cancer J. Clin. 2013, 63, 107-117.
6. Zhang, H. Osimertinib making a breakthrough in lung cancer targeted therapy. OncoTargets Ther. 2016, 9, 5489-5493.
7. Gridelli, C.; Peters, S.; Sgambato, A.; Casaluce, F.; Adjei, A.A.; Ciardiello, F. ALK inhibitors in the treatment of advanced NSCLC. Cancer Treat. Rev. 2014, 40, 300-306.
8. Bowles, D.W.; Weickhardt, A.J.; Doebele, R.C.; Camidge, D.R.; Jimeno, A. Crizotinib for the treatment of patients with advanced non-small cell lung cancer. Drugs Today 2012, 48, 271-282.
9. Richer, A.L.; Friel, J.M.; Carson, V.M.; Inge, L.J.; Whitsett, T.G. Genomic profiling toward precision medicine in non-small cell lung cancer: Getting beyond EGFR. Pharm. Pers. Med. 2015, 8, 63-79.
10. Chong, C.R.; Janne, P.A. The quest to overcome resistance to EGFR-targeted therapies in cancer. Nat. Med. 2013, 19, 1389-1400.
11. Tsuta, K.; Kohno, T.; Yoshida, A.; Shimada, Y.; Asamura, H.; Furuta, K.; Kushima, R. Ret-rearranged non-small-cell lung carcinoma: A clinicopathological and molecular analysis. Br. J. Cancer 2014, 110, 1571-1578.
12. Xiao, H.Q.; Tian, R.H.; Zhang, Z.H.; Du, K.Q.; Ni, Y.M. Efficacy of pemetrexed plus platinum doublet chemotherapy as first-line treatment for advanced nonsquamous non-small-cell-lung cancer: A systematic review and meta-analysis. OncoTargets Ther. 2016, 9, 1471-1476.
13. Maione, P.; Sacco, P.C.; Casaluce, F.; Sgambato, A.; Santabarbara, G.; Rossi, A.; Gridelli, C. Overcoming resistance to EGFR inhibitors in nsclc. Rev. Recent Clin. Trials 2016, 11, 99-105.
14. Li, Y.; Qi, K.; Zu, L.; Wang, M.; Wang, Y.; Zhou, Q. Anti-apoptotic brain and reproductive organ-expressed proteins enhance cisplatin resistance in lung cancer cells via the protein kinase B signaling pathway. Thorac. Cancer 2016, 7, 190-198.
15. Khagi, Y.; Kurzrock, R.; Patel, S.P. Next generation predictive biomarkers for immune checkpoint inhibition. Cancer Metastasis Rev. 2016.
16. Sacco, P.C.; Maione, P.; Guida, C.; Gridelli, C. The combination of new immunotherapy and radiotherapy: A new potential treatment for locally advanced non-small cell lung cancer. Curr. Clin. Pharmacol. 2016.
17. Sgambato, A.; Casaluce, F.; Sacco, P.C.; Palazzolo, G.; Maione, P.; Rossi, A.; Ciardiello, F.; Gridelli, C. Anti PD-1 and PDL-1 immunotherapy in the treatment of advanced non-small cell lung cancer (NSCLC): A review on toxicity profile and its management. Curr. Drug Saf. 2016, 11, 62-68.
18. Hatae, R.; Chamoto, K. Immune checkpoint inhibitors targeting programmed cell death-1 (PD-1) in cancer therapy. Rinsho Ketsueki 2016, 57, 2224-2231.
19. Shukuya, T.; Mori, K.; Amann, J.M.; Bertino, E.M.; Otterson, G.A.; Shields, P.G.; Morita, S.; Carbone, D.P. Relationship between overall survival and response or progression-free survival in advanced non-small cell lung cancer patients treated with Anti-PD-1/PD-L1 antibodies. J. Thorac. Oncol. 2016, 11, 1927-1939.
20. Lee, C.K.; Man, J.; Lord, S.; Links, M.; Gebski, V.; Mok, T.; Yang, J.C. Checkpoint inhibitors in metastatic EGFR-mutated non-small cell lung cancer-a meta-analysis. J. Thorac. Oncol. 2016.
21. Doll, R.; Peto, R. The causes of cancer: Quantitative estimates of avoidable risks of cancer in the united states today. J. Natl. Cancer Inst. 1981, 66, 1191-1308.
22. Doll, R.; Peto, R.; Wheatley, K.; Gray, R.; Sutherland, I. Mortality in relation to smoking: 40 years’ observations on male british doctors. BMJ 1994, 309, 901-911.
23. Carbone, D. Smoking and cancer. Am. J. Med. 1992, 93, 13S-17S.
24. Burch, P.R. Smoking and lung cancer. Tests of a causal hypothesis. J. Chronic Dis. 1980, 33, 221-238.
25. Morgan, W.K.; Seaton, A. Occupational Lung Diseases; W.B. Saunders: Philadelphia, PA, USA, 1984.
26. Min, K.B.; Min, J.Y. Serum carotenoid levels and risk of lung cancer death in us adults. Cancer Sci. 2014, 105, 736-743.
27. Gallicchio, L.; Boyd, K.; Matanoski, G.; Tao, X.G.; Chen, L.; Lam, T.K.; Shiels, M.; Hammond, E.; Robinson, K.A.; Caulfield, L.E. et al. Carotenoids and the risk of developing lung cancer: A systematic review. Am. J. Clin. Nutr. 2008, 88, 372-383.
28. Vieira, A.R.; Abar, L.; Vingeliene, S.; Chan, D.S.; Aune, D.; Navarro-Rosenblatt, D.; Stevens, C.; Greenwood, D.; Norat, T. Fruits, vegetables and lung cancer risk: A systematic review and meta-analysis. Ann. Oncol. 2016, 27, 81-96.
29. Peto, R.; Darby, S.; Deo, H.; Silcocks, P.; Whitley, E.; Doll, R. Smoking, smoking cessation, and lung cancer in the uk since 1950: Combination of national statistics with two case-control studies. BMJ 2000, 321, 323-329.
30. Flanders, W.D.; Lally, C.A.; Zhu, B.P.; Henley, S.J.; Thun, M.J. Lung cancer mortality in relation to age, duration of smoking, and daily cigarette consumption: Results from cancer prevention study ii. Cancer Res. 2003, 63, 6556-6562.
31. Mattson, M.E.; Pollack, E.S.; Cullen, J.W. What are the odds that smoking will kill you? Am. J. Public Health 1987, 77, 425-431.
32. Wood, D.E.; Eapen, G.A.; Ettinger, D.S.; Hou, L.; Jackman, D.; Kazerooni, E.; Klippenstein, D.; Lackner, R.P.; Leard, L.; Leung, A.N. et al. Lung cancer screening. J. Natl. Compr. Cancer Netw. 2012, 10, 240-265.
33. Silverberg, E. Cancer statistics, 1980. CA: Cancer J. Clin. 1980, 30, 23-38.
34. Shopland, D.R.; Eyre, H.J.; Pechacek, T.F. Smoking-attributable cancer mortality in 1991: Is lung cancer now the leading cause of death among smokers in the united states? J. Natl. Cancer Inst. 1991, 83, 1142-1148.
35. The Health Consequences of Smoking-50 Years of Progress: A Report of the Surgeon General. Available online: https://www.surgeongeneral.gov/library/reports/50-years-of-progress/full-report.pdf (accessed on 13 Spetember 2016).
36. Kondo, K.; Tsuzuki, H.; Sasa, M.; Sumitomo, M.; Uyama, T.; Monden, Y. A dose-response relationship between the frequency of p53 mutations and tobacco consumption in lung cancer patients. J. Surg. Oncol. 1996, 61, 20-26.
37. David, S.P.; Wang, A.; Kapphahn, K.; Hedlin, H.; Desai, M.; Henderson, M.; Yang, L.; Walsh, K.M.; Schwartz, A.G.; Wiencke, J.K. et al. Gene by environment investigation of incident lung cancer risk in african-americans. EBioMedicine 2016, 4, 153-161.
38. Zhang, Y.; Jiang, M.; Li, Q.; Liang, W.; He, Q.; Chen, W.; He, J. Chromosome 15q25 (CHRNA3-CHRNB4) variation indirectly impacts lung cancer risk in chinese males. PLoS ONE 2016, 11, e0149946.
39. Kosaka, T.; Yatabe, Y.; Endoh, H.; Kuwano, H.; Takahashi, T.; Mitsudomi, T. Mutations of the epidermal growth factor receptor gene in lung cancer: Biological and clinical implications. Cancer Res. 2004, 64, 8919-8923.
40. Mitsudomi, T. Molecular epidemiology of lung cancer and geographic variations with special reference to EGFR mutations. Transl. Lung Cancer Res. 2014, 3, 205-211.
41. Amos, C.I.; Wu, X.; Broderick, P.; Gorlov, I.P.; Gu, J.; Eisen, T.; Dong, Q.; Zhang, Q.; Gu, X.; Vijayakrishnan, J. et al. Genome-wide association scan of tag SNPs identifies a susceptibility locus for lung cancer at 15q25.1. Nat. Genet. 2008, 40, 616-622.
42. Hung, R.J.; McKay, J.D.; Gaborieau, V.; Boffetta, P.; Hashibe, M.; Zaridze, D.; Mukeria, A.; Szeszenia-Dabrowska, N.; Lissowska, J.; Rudnai, P. et al. A susceptibility locus for lung cancer maps to nicotinic acetylcholine receptor subunit genes on 15q25. Nature 2008, 452, 633-637.
43. Thorgeirsson, T.E.; Geller, F.; Sulem, P.; Rafnar, T.; Wiste, A.; Magnusson, K.P.; Manolescu, A.; Thorleifsson, G.; Stefansson, H.; Ingason, A. et al. A variant associated with nicotine dependence, lung cancer and peripheral arterial disease. Nature 2008, 452, 638-642.
44. Mitchell, P.; Mok, T.; Barraclough, H.; Strizek, A.; Lew, R.; van Kooten, M. Smoking history as a predictive factor of treatment response in advanced non-small-cell lung cancer: A systematic review. Clin. Lung Cancer 2012, 13, 239-251.
45. Stayner, L.; Bena, J.; Sasco, A.J.; Smith, R.; Steenland, K.; Kreuzer, M.; Straif, K. Lung cancer risk and workplace exposure to environmental tobacco smoke. Am. J. Public Health 2007, 97, 545-551.
46. Jenks, S. Is lung cancer incidence increasing in never-smokers? J. Natl. Cancer Inst. 2016, 108.
47. Mitsudomi, T.; Yatabe, Y. Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer. Cancer Sci. 2007, 98, 1817-1824.
48. Tokuhata, G.K.; Lilienfeld, A.M. Familial aggregation of lung cancer in humans. J. Natl. Cancer Inst. 1963, 30, 289-312.
49. Tokuhata, G.K.; Lilienfeld, A.M. Familial aggregation of lung cancer among hospital patients. Public Health Rep. 1963, 78, 277-283.
50. Ooi, W.L.; Elston, R.C.; Chen, V.W.; Bailey-Wilson, J.E.; Rothschild, H. Increased familial risk for lung cancer. J. Natl. Cancer Inst. 1986, 76, 217-222.
51. McDuffie, H.H. Clustering of cancer in families of patients with primary lung cancer. J. Clin. Epidemiol. 1991, 44, 69-76.
52. Cannon-Albright, L.A.; Thomas, A.; Goldgar, D.E.; Gholami, K.; Rowe, K.; Jacobsen, M.; McWhorter, W.P.; Skolnick, M.H. Familiality of cancer in utah. Cancer Res. 1994, 54, 2378-2385.
53. Goldgar, D.E.; Easton, D.F.; Cannon-Albright, L.A.; Skolnick, M.H. Systematic population-based assessment of cancer risk in first-degree relatives of cancer probands. J. Natl. Cancer Inst. 1994, 86, 1600-1608.
54. Etzel, C.J.; Amos, C.I.; Spitz, M.R. Risk for smoking-related cancer among relatives of lung cancer patients. Cancer Res. 2003, 63, 8531-8535.
55. Cote, M.L.; Kardia, S.L.; Wenzlaff, A.S.; Ruckdeschel, J.C.; Schwartz, A.G. Risk of lung cancer among white and black relatives of individuals with early-onset lung cancer. JAMA 2005, 293, 3036-3042.
56. Jonsson, S.; Thorsteinsdottir, U.; Gudbjartsson, D.F.; Jonsson, H.H.; Kristjansson, K.; Arnason, S.; Gudnason, V.; Isaksson, H.J.; Hallgrimsson, J.; Gulcher, J.R. et al. Familial risk of lung carcinoma in the icelandic population. JAMA 2004, 292, 2977-2983.
57. Matakidou, A.; Eisen, T.; Houlston, R.S. Systematic review of the relationship between family history and lung cancer risk. Br. J. Cancer 2005, 93, 825-833.
58. Cote, M.L.; Liu, M.; Bonassi, S.; Neri, M.; Schwartz, A.G.; Christiani, D.C.; Spitz, M.R.; Muscat, J.E.; Rennert, G.; Aben, K.K. et al. Increased risk of lung cancer in individuals with a family history of the disease: A pooled analysis from the international lung cancer consortium. Eur. J. Cancer 2012, 48, 1957-1968.
59. Schwartz, A.G.; Yang, P.; Swanson, G.M. Familial risk of lung cancer among nonsmokers and their relatives. Am. J. Epidemiol. 1996, 144, 554-562.
60. Mayne, S.T.; Buenconsejo, J.; Janerich, D.T. Familial cancer history and lung cancer risk in united states nonsmoking men and women. Am. Assoc. Cancer Res. 1999, 8, 1065-1069.
61. Sellers, T.A.; Bailey-Wilson, J.E.; Elston, R.C.; Wilson, A.F.; Elston, G.Z.; Ooi, W.L.; Rothschild, H. Evidence for mendelian inheritance in the pathogenesis of lung cancer. J. Natl. Cancer Inst. 1990, 82, 1272-1279.
62. Bailey-Wilson, J.E.; Sellers, T.A.; Elston, R.C.; Evens, C.C.; Rothschild, H. Evidence for a major gene effect in early-onset lung cancer. J. La. State Med. Soc. 1993, 145, 157-162.
63. Sellers, T.A.; Bailey-Wilson, J.E.; Potter, J.D.; Rich, S.S.; Rothschild, H.; Elston, R.C. Effect of cohort differences in smoking prevalence on models of lung cancer susceptibility. Genet. Epidemiol. 1992, 9, 261-271.
64. Sellers, T.A.; Potter, J.D.; Bailey-Wilson, J.E.; Rich, S.S.; Rothschild, H.; Elston, R.C. Lung cancer detection and prevention: Evidence for an interaction between smoking and genetic predisposition. Cancer Res. 1992, 52, 2694s-2697s.
65. Gauderman, W.J.; Morrison, J.L.; Carpenter, C.L.; Thomas, D.C. Analysis of gene-smoking interaction in lung cancer. Genet. Epidemiol. 1997, 14, 199-214.
66. Yang, P.; Schwartz, A.G.; McAllister, A.E.; Swanson, G.M.; Aston, C.E. Lung cancer risk in families of nonsmoking probands: Heterogeneity by age at diagnosis. Genet. Epidemiol. 1999, 17, 253-273.
67. Wu, P.F.; Lee, C.H.; Wang, M.J.; Goggins, W.B.; Chiang, T.A.; Huang, M.S.; Ko, Y.C. Cancer aggregation and complex segregation analysis of families with female non-smoking lung cancer probands in taiwan. Eur. J. Cancer 2004, 40, 260-266.
68. Broderick, P.; Wang, Y.; Vijayakrishnan, J.; Matakidou, A.; Spitz, M.R.; Eisen, T.; Amos, C.I.; Houlston, R.S. Deciphering the impact of common genetic variation on lung cancer risk: A genome-wide association study. Cancer Res. 2009, 69, 6633-6641.
69. Wang, Y.; Broderick, P.; Webb, E.; Wu, X.; Vijayakrishnan, J.; Matakidou, A.; Qureshi, M.; Dong, Q.; Gu, X.; Chen, W.V. et al. Common 5p15.33 and 6p21.33 variants influence lung cancer risk. Nat. Genet. 2008, 40, 1407-1409.
70. Timofeeva, M.N.; Hung, R.J.; Rafnar, T.; Christiani, D.C.; Field, J.K.; Bickeboller, H.; Risch, A.; McKay, J.D.; Wang, Y.; Dai, J. et al. Influence of common genetic variation on lung cancer risk: Meta-analysis of 14 900 cases and 29 485 controls. Hum. Mol. Genet. 2012, 21, 4980-4995.
71. Timofeeva, M.N.; McKay, J.D.; Smith, G.D.; Johansson, M.; Byrnes, G.B.; Chabrier, A.; Relton, C.; Ueland, P.M.; Vollset, S.E.; Midttun, O. et al. Genetic polymorphisms in 15q25 and 19q13 loci, cotinine levels, and risk of lung cancer in EPIC. Cancer Epidemiol. Biomark. Prev. 2011, 20, 2250-2261.
72. Saccone, N.L.; Wang, J.C.; Breslau, N.; Johnson, E.O.; Hatsukami, D.; Saccone, S.F.; Grucza, R.A.; Sun, L.; Duan, W.; Budde, J. et al. The CHRNA5-CHRNA3-CHRNB4 nicotinic receptor subunit gene cluster affects risk for nicotine dependence in African-Americans and in European-Americans. Cancer Res. 2009, 69, 6848-6856.
73. Hu, Z.; Wu, C.; Shi, Y.; Guo, H.; Zhao, X.; Yin, Z.; Yang, L.; Dai, J.; Hu, L.; Tan, W. et al. A genome-wide association study identifies two new lung cancer susceptibility loci at 13q12.12 and 22q12.2 in Han Chinese. Nat. Genet. 2011, 43, 792-796.
74. Dong, J.; Hu, Z.; Wu, C.; Guo, H.; Zhou, B.; Lv, J.; Lu, D.; Chen, K.; Shi, Y.; Chu, M. et al. Association analyses identify multiple new lung cancer susceptibility loci and their interactions with smoking in the Chinese population. Nat. Genet. 2012, 44, 895-899.
75. Shiraishi, K.; Kunitoh, H.; Daigo, Y.; Takahashi, A.; Goto, K.; Sakamoto, H.; Ohnami, S.; Shimada, Y.; Ashikawa, K.; Saito, A. et al. A genome-wide association study identifies two new susceptibility loci for lung adenocarcinoma in the Japanese population. Nat. Genet. 2012, 44, 900-903.
76. Qian, D.C.; Han, Y.H.; Byun, J.Y.; Shin, H.R.; Hung, R.J.; McLaughlin, J.R.; Landi, M.T.; Seminara, D.; Amos, C.I. A novel pathway-based approach improves lung cancer risk prediction using germline genetic variations. Cancer Epidem Biomark. 2016, 25, 1208-1215.
77. Qian, D.C.; Byun, J.Y.; Han, Y.H.; Greene, C.S.; Field, J.K.; Hung, R.J.; Brhane, Y.; Mclaughlin, J.R.; Fehringer, G.; Landi, M.T. et al. Identification of shared and unique susceptibility pathways among cancers of the lung, breast, and prostate from genome-wide association studies and tissue-specific protein interactions. Hum. Mol. Genet. 2015, 24, 7406-7420.
78. Bailey-Wilson, J.E.; Amos, C.I.; Pinney, S.M.; Petersen, G.M.; de Andrade, M.; Wiest, J.S.; Fain, P.; Schwartz, A.G.; You, M.; Franklin, W. et al. A major lung cancer susceptibility locus maps to chromosome 6q23-25. Am. J. Hum. Genet. 2004, 75, 460-474.
79. Lander, E.; Kruglyak, L. Genetic dissection of complex traits: Guidelines for interpreting and reporting linkage results. Nat. Genet. 1995, 11, 241-247.
80. Ott, J. Analysis of Human Genetic Linkage; Johns Hopkins University Press: Baltimore, MD, USA, 1985.
81. Amos, C.I.; Pinney, S.M.; Li, Y.; Kupert, E.; Lee, J.; de Andrade, M.A.; Yang, P.; Schwartz, A.G.; Fain, P.R.; Gazdar, A. et al. A susceptibility locus on chromosome 6q greatly increases lung cancer risk among light and never smokers. Cancer Res. 2010, 70, 2359-2367.
82. Park, K.J.; Choi, H.J.; Suh, S.P.; Ki, C.S.; Kim, J.W. Germline TP53 mutation and clinical characteristics of Korean patients with Li-Fraumeni syndrome. Ann. Lab. Med. 2016, 36, 463-468.
83. Zhuang, X.; Li, Y.; Cao, H.; Wang, T.; Chen, J.; Liu, J.; Lin, L.; Ye, R.; Li, X.; Liu, S. et al. Case report of a Li-Fraumeni syndrome-like phenotype with a de novo mutation in CHEK2. Medicine 2016.
84. De Kock, L.; Bah, I.; Wu, Y.; Xie, M.; Priest, J.R.; Foulkes, W.D. Germline and somatic DICER1 mutations in a well-differentiated fetal adenocarcinoma of the lung. J. Thorac. Oncol. 2016, 11, e31-e33.
85. Nathan, N.; Giraud, V.; Picard, C.; Nunes, H.; Dastot-Le Moal, F.; Copin, B.; Galeron, L.; De Ligniville, A.; Kuziner, N.; Reynaud-Gaubert, M. et al. Germline SFTPA1 mutation in familial idiopathic interstitial pneumonia and lung cancer. Hum. Mol. Genet. 2016, 25, 1457-1467.
86. Bell, D.W.; Gore, I.; Okimoto, R.A.; Godin-Heymann, N.; Sordella, R.; Mulloy, R.; Sharma, S.V.; Brannigan, B.W.; Mohapatra, G.; Settleman, J. et al. Inherited susceptibility to lung cancer may be associated with the T790M drug resistance mutation in egfr. Nat. Genet. 2005, 37, 1315-1316.
87. Thomas, A.; Xi, L.Q.; Carter, C.A.; Rajan, A.; Khozin, S.; Szabo, E.; Dennis, P.A.; Giaccone, G.; Raffeld, M. Concurrent molecular alterations in tumors with germ line epidermal growth factor receptor T790M mutations. Clin. Lung Cancer 2013, 14, 452-456.
88. Lou, Y.; Pecot, C.V.; Tran, H.T.; DeVito, V.J.; Tang, X.M.; Heymach, J.V.; Luthra, R.; Wistuba, I.I.; Zuo, Z.; Tsao, A.S. Germline mutation of T790M and dual/multiple EGFR mutations in patients with lung adenocarcinoma. Clin. Lung Cancer 2016, 17, e5-e11.
89. Yu, H.A.; Arcila, M.E.; Fleischut, M.H.; Stadler, Z.; Ladanyi, M.; Berger, M.F.; Robson, M.; Riely, G.J. Germline EGFR T790M mutation found in multiple members of a familial cohort. J. Thorac. Oncol. 2014, 9, 554-558.
90. Gazdar, A.; Robinson, L.; Oliver, D.; Xing, C.; Travis, W.D.; Soh, J.; Toyooka, S.; Watumull, L.; Xie, Y.; Kernstine, K, et al. Hereditary lung cancer syndrome targets never smokers with germline EGFR gene T790M mutations. J. Thorac. Oncol. 2014, 9, 456-463.
91. Yamamoto, H.; Higasa, K.; Sakaguchi, M.; Shien, K.; Soh, J.; Ichimura, K.; Furukawa, M.; Hashida, S.; Tsukuda, K.; Takigawa, N. et al. Novel germline mutation in the transmembrane domain of HER2 in familial lung adenocarcinomas. J. Natl. Cancer Inst. 2014.
92. Abdel-Rahman, M.H.; Pilarski, R.; Cebulla, C.M.; Massengill, J.B.; Christopher, B.N.; Boru, G.; Hovland, P.; Davidorf, F.H. Germline BAP1 mutation predisposes to uveal melanoma, lung adenocarcinoma, meningioma, and other cancers. J. Med. Genet. 2011, 48, 856-859.
93. Xiong, D.; Wang, Y.; Kupert, E.; Simpson, C.; Pinney, S.M.; Gaba, C.R.; Mandal, D.; Schwartz, A.G.; Yang, P.; de Andrade, M. et al. A recurrent mutation in PARK2 is associated with familial lung cancer. Am. J. Hum. Genet. 2015, 96, 301-308.
94. You, M.; Wang, D.L.; Liu, P.Y.; Vikis, H.; James, M.; Lu, Y.; Wang, Y.; Wang, M.; Chen, Q.O.; Jia, D.M. et al. Fine mapping of chromosome 6q23-25 region in familial lung cancer families reveals RGS17 as a likely candidate gene. Clin. Cancer Res. 2009, 15, 2666-2674.
95. U.S. Government Clinical Trials Website. Available online: https://clinicaltrials.gov/ct2/results?term=inherited+lung+cancer+risk&Search=Search (accessed on 21 December 2016).